Jonathan Himmelfarb, M.D.

Director of KRI, University of Washington Professor of Medicine, Holder of the Joseph W. Eschbach Endowed Chair in Kidney Research

Kidney Research Institute
University of Washington
Box 359606
325 9th ave
Seattle, WA 98104

P: (206) 744-4932

F: (206) 685-9399


Education and Training

Medical School
George Washington University
Washington, DC

Medical Residency
Maine Medical Center
Portland, ME

Nephrology Fellowship
Maine Medical Center
Portland, ME

Nephrology Fellowship
Brigham & Women's Hospital
Boston, MA

Research Interests

Oxidative stress and inflammation in chronic kidney disease

Biomarkers of cardiovascular risk in kidney disease

Dialysis vascular access

Mechanisms of proteinuria


Himmelfarb J, Shankland, SJ. Creating research infrastructure and functionality to address chronic kidney disease: the Kidney Research Institute. Seminars in Nephrology, 29:457-66, 2009.

Nolin TD, Frye, RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J, ESRD impairs nonrenal clearance of fexofenadine but not midazolam, J Am Soc Nephrol, 20(10): 2269-76, 2009.

Himmelfarb J: Success and Challenge in Dialysis Therapy. N Eng J Med, 347:2068-2070, 2002

Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med.; 363:1833-45, 2010.

de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States, JAMA. 2011,305; 2532-9

Himmelfarb J. Optimizing patient safety during hemodialysis, JAMA. 2011;15: 1707-8.